Catherine Wood's NRIX Position Overview
Catherine Wood (via Ark Investment Management LLC) currently holds 1.6 M shares of Nurix Therapeutics, Inc. (NRIX) worth $30.4 M, representing 0.20% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Catherine Wood has maintained a strategic position in NRIX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2022, adding 701,732 shares. Largest reduction occurred in Q4 2024, reducing 686,072 shares.
Analysis based on 13F filings available since 2013 Q2
Catherine Wood's Nurix Therapeutics (NRIX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Nurix Therapeutics (NRIX) Trades by Catherine Wood
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +92,135 | Add 6.10% | 1.6 M | $18.97 |
| Q3 2025 | -64,628 | Reduce 4.10% | 1.51 M | $9.24 |
| Q2 2025 | -15,878 | Reduce 1.00% | 1.58 M | $11.39 |
| Q1 2025 | +60,617 | Add 3.96% | 1.59 M | $11.88 |
| Q4 2024 | -686,072 | Reduce 30.95% | 1.53 M | $18.84 |
| Q3 2024 | -106,967 | Reduce 4.60% | 2.22 M | $22.47 |
| Q2 2024 | -312,006 | Reduce 11.84% | 2.32 M | $20.87 |
| Q1 2024 | -559,661 | Reduce 17.52% | 2.64 M | $14.70 |
| Q4 2023 | +601,952 | Add 23.21% | 3.19 M | $10.32 |
| Q3 2023 | +331,976 | Add 14.68% | 2.59 M | $7.86 |
| Q2 2023 | +21,212 | Add 0.95% | 2.26 M | $9.99 |
| Q1 2023 | +251,605 | Add 12.65% | 2.24 M | $8.88 |
| Q4 2022 | +701,732 | Add 54.54% | 1.99 M | $10.98 |
| Q3 2022 | +507,797 | Add 65.21% | 1.29 M | $13.03 |
| Q2 2022 | +386,734 | Add 98.66% | 778,725 | $10.09 |
| Q1 2022 | +348,044 | Add 791.96% | 391,991 | $14.01 |
| Q4 2021 | +43,947 | New Buy | 43,947 | $28.94 |
Catherine Wood's Nurix Therapeutics Investment FAQs
Catherine Wood first purchased Nurix Therapeutics, Inc. (NRIX) in Q4 2021, acquiring 43,947 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood has held Nurix Therapeutics, Inc. (NRIX) for 17 quarters since Q4 2021.
Catherine Wood's largest addition to Nurix Therapeutics, Inc. (NRIX) was in Q4 2022, adding 1,988,254 shares worth $21.83 M.
According to the latest 13F filing for Q4 2025, Catherine Wood's firm, Ark Investment Management LLC, owns 1,602,539 shares of Nurix Therapeutics, Inc. (NRIX), valued at approximately $30.4 M.
As of the Q4 2025 filing, Nurix Therapeutics, Inc. (NRIX) represents approximately 0.20% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings.
Catherine Wood's peak holding in Nurix Therapeutics, Inc. (NRIX) was 3,194,999 shares, as reported at the end of Q4 2023.